Sibling stem cell transplant with donor T cells for high-risk leukemia
Tests a sibling stem cell transplant with donor T cells in adults with high-risk leukemia.
Plain-language title generated from the registry record
Registry title: Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
Key facts
- Where
- Perugia and Pescara, ItalySee the 2 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07552649, who can take part
Where in Italy
- Azienda Ospedaliera di Perugia;Ospedale S. Maria della MisericordiaPerugia, ItalyNo longer taking part
- Presidio Ospedaliero Pescara - Azienda Sanitaria Locale di PescaraPescara, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Antonio Pierini
- Trial code
- NCT07552649
- Record updated
- 27 April 2026
- Original description
The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML patients.Read full original descriptionShow less
MATCH-Treg: Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia
The study is a multicentric, interventional study that evaluates the efficacy of allogeneic HLA-matched allo-HSCT consisting of myeloablative conditioning coupled with donor Treg/Tcon adoptive immunotherapy for high-risk AML patients.
Inclusion: Diagnosis of AML with adverse genetic mutations in Complete Remission (CR) or incomplete (i) CR according to ELN 2022 recommendations with or without MRD positivity at the time of the HSCT procedure; Diagnosis of AML with intermediate genetic mutations in Complete remission (CR) or incomplete (i) CR according to ELN 2022 with MRD positivity at the time of the transplant; Fitness to undergo allo-HCT with myeloablative conditioning regimens according to center policy; Availability of a family HLA-matched hematopoietic stem cell donor suitable to be treated with G-CSF (10 mcg/kg/die) for a maximum of 7 days and able to tolerate 2 or more leukaphereses; Age ≥ 18 and ≤ 70 years; ECOG ≤ 2; HCT-CI ≤ 4; Signature of the informed consent.
Exclusion: Prior allo-HSCT; Active disease at transplant (> 5% bone marrow infiltration); Unacceptable lung, liver, kidney, and/or heart function and presence of relevant psychiatric diseases according to clinical judgment; Uncontrolled bacterial, viral, or fungal infections at time of enrollment; Age < 18 years or > 70 years; AML with favorable genetic abnormalities; AML with intermediate genetic risk with MRD negativity; Availability of a haploidentical or matched unrelated donor (MUD); ECOG > 2; Pregnancy; No signature of the informed consent.